Anxiety · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment response (post‐treatment score on self report and clinician‐rated scales) · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional disability and quality of life (post‐treatment score on self report and clinician‐rated scales) · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report and clinician‐rated scales (SOMS‐7, SCL‐90 Somatisation Score) · somatoform disorders in adults
1 finding from 1 review
Acceptability · somatoform disorders in adults
New‐generation antidepressants showed no clear difference in acceptability (all‐cause drop‐outs) compared with placebo (low certainty).
1 finding from 1 review
Endpoint International Index of Erectile Function (IIEF) total scores (The IIEF is a self‐report measure with 15 questions examining erectile function, orgasmic function, sexual desire, and intercourse satisfaction. Maximum possible score 75) · people with antidepressant‐induced sexual dysfunction
1 finding from 1 review
Endpoint International Index of Erectile Function (IIEF) scores ‐ question 3: ability to achieve erection (Maximum score 5) · people with antidepressant‐induced sexual dysfunction
1 finding from 1 review
Endpoint International Index of Erectile Function (IIEF) scores ‐ intercourse satisfaction (questions 6, 7, 8) (Maximum score 15) · people with antidepressant‐induced sexual dysfunction
1 finding from 1 review
Effect on later sexual function · people with antidepressant‐induced sexual dysfunction
Sildenafil probably leads to lower clinical Global Impression ‐Sexual Function not "much/very much… compared with placebo (moderate certainty).
1 finding from 1 review
Dropout · people with antidepressant‐induced sexual dysfunction
Sildenafil showed no clear difference in dropouts (People leaving the trial early) compared with placebo (high certainty).
1 finding from 1 review
Global Efficacy Questionnaire (questions 1 & 2) (Questions assessing improvement attributed to medication compared to having no treatment at all) · people with antidepressant‐induced sexual dysfunction
Sildenafil probably leads to higher global Efficacy Questionnaire (questions 1 & 2) (Questions assessing… compared with placebo (moderate certainty).
1 finding from 1 review
Endpoint scale total scores (150 mg twice daily dose) (Scales of sexual functioning. As studies used different scales to assess sexual functioning, differences are expressed as standardised mean differences (SMD)) · people with antidepressant‐induced sexual dysfunction
1 finding from 1 review
Effect on later sexual function · people with antidepressant‐induced sexual dysfunction
Bupropion showed no clear difference in 50% reduction in score on the Arizona Sexual Experiences Scale… compared with placebo (moderate certainty).
1 finding from 1 review
Dropout · people with antidepressant‐induced sexual dysfunction
Bupropion showed no clear difference in dropouts (People leaving the trial early) compared with placebo (high certainty).
1 finding from 1 review
Mean change in YMRS from baseline at three weeks Young Mania Rating Scale (YMRS): an 11‐item questionnaire to assess the severity of core symptoms of mania. Scale from 0 to 60 · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
1819 participants
Moderate
≥ 50% decrease in total YMRS from baseline at three weeks Young Mania Rating Scale (as above) · patients with an acute manic or mixed episode
Aripiprazole probably leads to higher ≥ 50% decrease in total YMRS from baseline at three weeks Young… compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.7 [1.23, 2.34]
1230 participants
Moderate
Numbers completing double‐blind treatment Number of participants · patients with an acute manic or mixed episode
Aripiprazole showed no clear difference in numbers completing double‐blind treatment Number of participants compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.03 [0.95, 1.12]
2216 participants
Moderate
Requirement for anticholinergics number of participants requiring medication for extrapyramidal side effects · patients with an acute manic or mixed episode
Aripiprazole leads to higher requirement for anticholinergics number of participants requiring… compared with placebo (high certainty).
1 finding from 1 review
RR 3.28 [1.82, 5.91]
730 participants
High